Fresenius Kabi AG
www.fresenius-kabi.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Fresenius Kabi AG
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.
Fresenius Divests Norwegian Plant To Prange
Fresenius Kabi has completed the divestment of a manufacturing plant in Halden, Norway, to Prange Group.
Fresenius Claims Edge With US Tocilizumab Biosimilar Approval
Fresenius Kabi has claimed an advantage in the biosimilar tocilizumab arena after its Tyenne rival to Actemra was approved by the US FDA in both intravenous and subcutaneous formulations.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Medical Devices
- Infusion Therapy Equipment and Supplies
- Other Names / Subsidiaries
-
- mAbxience S.L.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice